Cargando…

The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?

Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Spenlé, Caroline, Lefebvre, Olivier, Lacroute, Joël, Méchine-Neuville, Agnès, Barreau, Frédérick, Blottière, Hervé M., Duclos, Bernard, Arnold, Christiane, Hussenet, Thomas, Hemmerlé, Joseph, Gullberg, Donald, Kedinger, Michèle, Sorokin, Lydia, Orend, Gertraud, Simon-Assmann, Patricia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210184/
https://www.ncbi.nlm.nih.gov/pubmed/25347196
http://dx.doi.org/10.1371/journal.pone.0111336
_version_ 1782341339793326080
author Spenlé, Caroline
Lefebvre, Olivier
Lacroute, Joël
Méchine-Neuville, Agnès
Barreau, Frédérick
Blottière, Hervé M.
Duclos, Bernard
Arnold, Christiane
Hussenet, Thomas
Hemmerlé, Joseph
Gullberg, Donald
Kedinger, Michèle
Sorokin, Lydia
Orend, Gertraud
Simon-Assmann, Patricia
author_facet Spenlé, Caroline
Lefebvre, Olivier
Lacroute, Joël
Méchine-Neuville, Agnès
Barreau, Frédérick
Blottière, Hervé M.
Duclos, Bernard
Arnold, Christiane
Hussenet, Thomas
Hemmerlé, Joseph
Gullberg, Donald
Kedinger, Michèle
Sorokin, Lydia
Orend, Gertraud
Simon-Assmann, Patricia
author_sort Spenlé, Caroline
collection PubMed
description Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue maintenance, and in cancer progression which represents an inherent risk of IBD. Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chains are specifically and ectopically overexpressed with a concomitant nuclear p53 accumulation. Linked to this observation, we provided a mechanism showing that p53 induces LMα1 expression at the promoter level by ChIP analysis and this was confirmed by knockdown in cell transfection experiments. To mimic the human disease, we induced colitis and colitis-associated cancer by chemical treatment (DSS) combined or not with a carcinogen (AOM) in transgenic mice overexpressing LMα1 or LMα5 specifically in the intestine. We demonstrated that high LMα1 or LMα5 expression decreased susceptibility towards experimentally DSS-induced colon inflammation as assessed by histological scoring and decrease of pro-inflammatory cytokines. Yet in a pro-oncogenic context, we showed that LM would favor tumorigenesis as revealed by enhanced tumor lesion formation in both LM transgenic mice. Altogether, our results showed that nuclear p53 and associated overexpression of LMα1 and LMα5 protect tissue from inflammation. But in a mutation setting, the same LM molecules favor progression of IBD into colitis-associated cancer. Our transgenic mice represent attractive new models to acquire knowledge about the paradoxical effect of LM that mediate either tissue reparation or cancer according to the microenvironment. In the early phases of IBD, reinforcing basement membrane stability/organization could be a promising therapeutic approach.
format Online
Article
Text
id pubmed-4210184
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42101842014-10-30 The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy? Spenlé, Caroline Lefebvre, Olivier Lacroute, Joël Méchine-Neuville, Agnès Barreau, Frédérick Blottière, Hervé M. Duclos, Bernard Arnold, Christiane Hussenet, Thomas Hemmerlé, Joseph Gullberg, Donald Kedinger, Michèle Sorokin, Lydia Orend, Gertraud Simon-Assmann, Patricia PLoS One Research Article Laminins (LM), basement membrane molecules and mediators of epithelial-stromal communication, are crucial in tissue homeostasis. Inflammatory Bowel Diseases (IBD) are multifactorial pathologies where the microenvironment and in particular LM play an important yet poorly understood role in tissue maintenance, and in cancer progression which represents an inherent risk of IBD. Here we showed first that in human IBD colonic samples and in murine colitis the LMα1 and LMα5 chains are specifically and ectopically overexpressed with a concomitant nuclear p53 accumulation. Linked to this observation, we provided a mechanism showing that p53 induces LMα1 expression at the promoter level by ChIP analysis and this was confirmed by knockdown in cell transfection experiments. To mimic the human disease, we induced colitis and colitis-associated cancer by chemical treatment (DSS) combined or not with a carcinogen (AOM) in transgenic mice overexpressing LMα1 or LMα5 specifically in the intestine. We demonstrated that high LMα1 or LMα5 expression decreased susceptibility towards experimentally DSS-induced colon inflammation as assessed by histological scoring and decrease of pro-inflammatory cytokines. Yet in a pro-oncogenic context, we showed that LM would favor tumorigenesis as revealed by enhanced tumor lesion formation in both LM transgenic mice. Altogether, our results showed that nuclear p53 and associated overexpression of LMα1 and LMα5 protect tissue from inflammation. But in a mutation setting, the same LM molecules favor progression of IBD into colitis-associated cancer. Our transgenic mice represent attractive new models to acquire knowledge about the paradoxical effect of LM that mediate either tissue reparation or cancer according to the microenvironment. In the early phases of IBD, reinforcing basement membrane stability/organization could be a promising therapeutic approach. Public Library of Science 2014-10-27 /pmc/articles/PMC4210184/ /pubmed/25347196 http://dx.doi.org/10.1371/journal.pone.0111336 Text en © 2014 Spenlé et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Spenlé, Caroline
Lefebvre, Olivier
Lacroute, Joël
Méchine-Neuville, Agnès
Barreau, Frédérick
Blottière, Hervé M.
Duclos, Bernard
Arnold, Christiane
Hussenet, Thomas
Hemmerlé, Joseph
Gullberg, Donald
Kedinger, Michèle
Sorokin, Lydia
Orend, Gertraud
Simon-Assmann, Patricia
The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title_full The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title_fullStr The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title_full_unstemmed The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title_short The Laminin Response in Inflammatory Bowel Disease: Protection or Malignancy?
title_sort laminin response in inflammatory bowel disease: protection or malignancy?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210184/
https://www.ncbi.nlm.nih.gov/pubmed/25347196
http://dx.doi.org/10.1371/journal.pone.0111336
work_keys_str_mv AT spenlecaroline thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT lefebvreolivier thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT lacroutejoel thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT mechineneuvilleagnes thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT barreaufrederick thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT blottierehervem thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT duclosbernard thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT arnoldchristiane thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT hussenetthomas thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT hemmerlejoseph thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT gullbergdonald thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT kedingermichele thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT sorokinlydia thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT orendgertraud thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT simonassmannpatricia thelamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT spenlecaroline lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT lefebvreolivier lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT lacroutejoel lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT mechineneuvilleagnes lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT barreaufrederick lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT blottierehervem lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT duclosbernard lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT arnoldchristiane lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT hussenetthomas lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT hemmerlejoseph lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT gullbergdonald lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT kedingermichele lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT sorokinlydia lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT orendgertraud lamininresponseininflammatoryboweldiseaseprotectionormalignancy
AT simonassmannpatricia lamininresponseininflammatoryboweldiseaseprotectionormalignancy